Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3690 - The colorectal cancer (CRC) tumour microenvironment recruits and polarises two distinct populations of myeloid cells with unique regulatory profiles

Date

10 Oct 2016

Session

Poster display

Presenters

Louise Elliott

Citation

Annals of Oncology (2016) 27 (6): 545-551. 10.1093/annonc/mdw393

Authors

L.A. Elliott1, K. Sheahan2, G. Doherty2, D. Fennelly3, E. Ryan2

Author affiliations

  • 1 Erc, St.vincent's University Hospital, Dublin City University, 4 - Dublin/IE
  • 2 Centre For Colorectal Disease, St Vincents University Hospital, 4 - Dublin/IE
  • 3 Oncology, St Vincents University Hospital, 4 - Dublin/IE
More

Resources

Abstract 3690

Background

Tumor resident myeloid cells (MCs) are instrumental to cancer progression and are emerging as a potential therapeutic target in many cancers. The mechanisms by which tumours regulate MCs remain poorly defined. We investigated how the CRC tumour microenvironment (TME) impacts on MCs recruitment and function.

Methods

Patients with Stage II/III CRC undergoing surgical resection were recruited (n = 21). Fresh samples of tumour and uninvolved tissue were obtained and digested to a single cell suspension. MCs were phenotyped using multi-parameter flow cytometry. We generated tumor (TCM) and normal (NCM) conditioned media from a further cohort (n = 40) and assessed levels of 16 cytokines using a multiplex assay. Finally, we designed a MC:Cell line co-culture model to investigate the molecular mechanisms that control MC function.

Results

We found two distinct MC subsets, HLA-DRhiCD11chi and CD11bhiCD15hi, unique to the tumor tissue, dominated the CD45+ compartment. Further analysis showed that the HLA-DRhiCD11chi and the CD11bhiCD15hi were of monocyte and neutrophil origin, respectively. In support of their potential immune-regulatory and proangiogenic function, we showed that the HLA-DRhiCD11chi subset expressed ILT4, PDL1 and Tie-2. The CD11bhiCD15hi subset exhibited high levels of arginase, an enzyme involved in T cell suppression. Interestingly, both cell subsets displayed an altered chemokine receptor profile compared to their blood counterparts. Accordingly, we were able to confirm the upregulated expression of inflammatory mediators, CXCL1 (p 

Conclusions

This study identifies two MC subsets in patients with CRC. We demonstrate that the TME recruits these cells via a complex chemokine-chemokine receptor network subsequently transforming them into a highly activated but immune-regulatory cell that favors tumor growth.

Clinical trial identification

Legal entity responsible for the study

Louise Elliott

Funding

Merck Serono

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings